NASDAQ:GLYC - GlycoMimetics Stock Price, Forecast & News

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

GlycoMimetics Inc (NASDAQ:GLYC) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.08. View GlycoMimetics' Earnings History.

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for GlycoMimetics.

6 brokerages have issued 12-month target prices for GlycoMimetics' shares. Their forecasts range from $5.00 to $18.00. On average, they anticipate GlycoMimetics' stock price to reach $9.25 in the next year. This suggests a possible upside of 54.4% from the stock's current price. View Analyst Price Targets for GlycoMimetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.

News articles about GLYC stock have trended somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GlycoMimetics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the company's share price in the immediate future. View News Stories for GlycoMimetics.

GlycoMimetics saw a decline in short interest during the month of October. As of October 15th, there was short interest totalling 3,620,000 shares, a decline of 6.7% from the September 15th total of 3,880,000 shares. Based on an average trading volume of 867,000 shares, the days-to-cover ratio is currently 4.2 days. Currently, 10.9% of the shares of the stock are short sold. View GlycoMimetics' Current Options Chain.

Some companies that are related to GlycoMimetics include Radius Health (RDUS), Rocket Pharmaceuticals (RCKT), ZEALAND PHARMA/S (ZEAL), Phibro Animal Health (PAHC), ZIOPHARM Oncology (ZIOP), Vanda Pharmaceuticals (VNDA), Amphastar Pharmaceuticals (AMPH), Achillion Pharmaceuticals (ACHN), Stoke Therapeutics (STOK), Synthorx (THOR), Dova Pharmaceuticals (DOVA), Homology Medicines (FIXX), G1 Therapeutics (GTHX), CannTrust (CNTTF) and TG Therapeutics (TGTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), Viking Therapeutics (VKTX), Progenics Pharmaceuticals (PGNX), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Coherus Biosciences (CHRS), Dynavax Technologies (DVAX), Fate Therapeutics (FATE), Heron Therapeutics (HRTX) and Nektar Therapeutics (NKTR).

GlycoMimetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Redmile Group LLC (4.61%), State Street Corp (1.54%), Millennium Management LLC (0.53%), Alps Advisors Inc. (0.20%), Squarepoint Ops LLC (0.11%) and Barclays PLC (0.09%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, Helen M Thackray, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.

GLYC stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Redmile Group LLC and Alps Advisors Inc.. View Insider Buying and Selling for GlycoMimetics.

GLYC stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Squarepoint Ops LLC, Prentiss Smith & Co. Inc., Tower Research Capital LLC TRC, California Public Employees Retirement System and Barclays PLC. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il and Daniel M Junius. View Insider Buying and Selling for GlycoMimetics.

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GLYC stock can currently be purchased for approximately $5.99.

GlycoMimetics has a market capitalization of $259.73 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.

The official website for GlycoMimetics is http://www.glycomimetics.com/.

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]